Ardea Biosciences (RDEA +6%) is trading higher after saying earlier that it's completed its...

|About: Ardea Biosciences, Inc. (RDEA)|By:, SA News Editor

Ardea Biosciences (RDEA +6%) is trading higher after saying earlier that it's completed its end-of-phase 2 meetings with the FDA, and has reached an agreement on key aspects of its proposed lesinurad development plan for phase 3.